这家公司手握“全球唯一”！现要IPO！

Core Insights - Danno Pharmaceuticals (Suzhou) Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, with CITIC Securities and Agricultural Bank of China International as joint sponsors [1] - The company focuses on developing innovative drugs for bacterial infections and related diseases, with three core products including TNP-2198, the world's first and only new molecular entity candidate for treating Helicobacter pylori infection [2][3] Financial Performance - Danno Pharmaceuticals reported a net loss of approximately 338 million yuan over the past two years, primarily due to R&D expenses, administrative costs, and financial costs, with R&D expenses accounting for 90.7% and 82% of total costs in 2023 and 2024 respectively [3] - The company’s operating losses for 2023, 2024, and Q1 2025 were approximately 122 million yuan, 77.8 million yuan, and 17.1 million yuan, respectively [3] Product Development - The company has completed a Phase III head-to-head clinical trial for TNP-2198 and plans to submit a New Drug Application (NDA) to the National Medical Products Administration by the end of August 2025 [3] - TNP-2198 utilizes a unique multi-target mechanism to combat antibiotic resistance, which is a significant global challenge [2] Funding and Valuation - Danno Pharmaceuticals has completed multiple funding rounds since its establishment in 2013, with the latest E round raising over 300 million yuan, bringing the post-money valuation to 2.013 billion yuan [4] - The company has pledged six core patents to secure bank loans, with a total intellectual property financing scale of 150 million yuan [4] Shareholding Structure - The largest shareholder is an entity controlled by Meyerson and family members, holding approximately 18.82% of the company, while the founder and CEO, Ma Zhenkun, holds 3.16% [4] - Other notable shareholders include WuXi AppTec, Northern Light Venture Capital, AMR Action Fund, Yuanhe Holdings, and Gaotejia [4]